Magnolol, which is a CYP3A substrate, is a well-known agent that can facilitate\nneuroprotection and reduce ischemic brain damage. However, a well-controlled release formulation\nis needed for the effective delivery of magnolol due to its poor water solubility. In this study,\nwe have developed a formulation for a CYP3A-excipient microemulsion, which can be administrated\nintraperitoneally to increase the solubility and bioavailability of magnolol and increase its\nneuroprotective effect against ischemic brain injury. The results showed a significant improvement\nin the area under the plotted curve of drug concentration versus time curve (AUC0â??t) and mean\nresidence time (MRT) of magnolol in microemulsion compared to when it was dissolved in dimethyl\nsulfoxide (DMSO). Both magnolol in DMSO and microemulsion, administrated after the onset of\nischemia, showed a reduced visual brain infarct size. As such, this demonstrates a therapeutic effect on\nischemic brain injury caused by occlusion, however it is important to note that a pharmacological effect\ncannot be concluded by this study. Ultimately, our study suggests that the excipient inhibitor-based\nmicroemulsion formulation could be a promising concept for the substrate drugs of CYP3A.
Loading....